Belgian Journal of Paediatrics
Impact of RSV Immunization with Nirsevimab (Beyfortus®) on RSV-Related Hospitalizations of Pediatric Patients in a Regional Hospital in Belgium
Vol. 27 No. 1 (2025), Brief communications
Vol. 27 No. 1 (2025)

Impact of RSV Immunization with Nirsevimab (Beyfortus®) on RSV-Related Hospitalizations of Pediatric Patients in a Regional Hospital in Belgium

Brief communications
Published 2025-04-29
Cato Dessers
Faculty of Medicine, KU Leuven, Leuven, Belgium ; Jessa Hospital, Department of Pediatrics, Hasselt, Belgium
Manon Willekens
Faculty of Medicine, KU Leuven, Leuven, Belgium
Aylin Özen
Faculty of Medicine, VU Brussel, Brussels, Belgium
Marcelien Verjans
Faculty of Medicine, KU Leuven, Leuven, Belgium
Hannelore Van Gool
Faculty of Medicine, KU Leuven, Leuven, Belgium
Marie-Paule Verjans
Pediatricians, Huis 5, Hasselt, Belgium
Marc Raes
Jessa Hospital, Department of Pediatrics, Hasselt, Belgium ; Pediatricians, Huis 5, Hasselt, Belgium
PDF

Keywords

respiratory syncytial virus
immunization
nirsevimab
hospitalization
child

Categories

How to Cite

Dessers, C., Willekens, M., Özen, A., Verjans, M., Van Gool, H., Verjans, M.-P., & Raes, M. (2025). Impact of RSV Immunization with Nirsevimab (Beyfortus®) on RSV-Related Hospitalizations of Pediatric Patients in a Regional Hospital in Belgium. Belgian Journal of Paediatrics, 27(1), 61–62. Retrieved from https://belgjpaediatrics.com/index.php/bjp/article/view/378
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Respiratory infections caused by respiratory syncytial virus (RSV) are a significant cause of hospitalizations in young children. This study evaluates the impact of immunization with nirsevimab (Beyfortus®) on RSV-related hospitalizations and severity of outcome at Jessa Hospital, Belgium. Comparing pre- and post-immunization periods, data from the 2024–2025 RSV season show a reduction in hospitalizations, with a notable 78.7% decrease in infants under 6 months comparing to last season. Immunization resulted in reduced oxygen and Optiflow® need. Findings suggest that nirsevimab decreases hospitalizations and severity of RSV infections.

PDF